Table 1. Characteristics of patients... | American Society of Hematology

Table 1.

Characteristics of patients with chemotherapy-resistant AML (rAML) and chemotherapy-sensitive AML (sAML)

Patient	FAB	Karyotype	Age	Disease state of blasts obtained^*	Chemotherapy, including AraC	Material	Blasts before FACS, %	Leukemic-specific markers used for FACS	Blasts after FACS, %
rAML1	M0	t(3;6), del(11), del(12)	38	Relapse	3	BM	95	CD33/34	>95
rAML2	M0	Normal	60	Relapse	2	BM	90	CD13/34	>99.5
rAML3	M2	t(8;21), t(1;10)(minor)	42	Relapse	3	BM	75	CD33/34	99
rAML4	M5A	t(9;11)	22	Relapse	2	BM	80	CD33/HLA-DR	98
rAML5	M2	t(1;9), del(6)	21	Relapse	3	PB	35	CD13/14/33/45	>95
rAML6	M6	Unknown	34	Refractory	2	BM	35	CD15/33	95
rAML7	M1	t(9;22), inv(3), −7	41	Refractory	2	PB	>90	CD34/54	>99.9
rAML8	M5	Unknown	50	Refractory	3	BM	80	CD33/HLA-DR	>95
rAML9	M3	+(13)	56	Refractory	3	BM	97	No sort	97
rAML10	M2	Unknown	53	Refractory	3	BM	94	CD33/34	>95
rAML11	M2	Normal	68	Diagnosis	0	BM	50	CD13/14/33	>95
rAML12	M1	Del(7)	57	Diagnosis	0	BM	95	No sort	95
sAML1	M1	Normal	44	Diagnosis	0	BM	95	No sort	95
sAML2	M5A	Normal	48	Diagnosis	0	BM	95	No sort	95
sAML3	M5A	t(9;11), +8	55	Diagnosis	0	BM	93	CD33/HLA-DR	98.5
sAML4	M4	Unknown	46	Diagnosis	0	BM	60	CD33/HLA-DR	>95
sAML5	M5	t(8;21)	55	Diagnosis	0	BM	96	No sort	96
sAML6	M4	Inv(16), +8, +14, +21	48	Diagnosis	0	BM	60	CD13/CD65	>98
sAML7	M2	t(8;21)	17	Diagnosis	0	PB	75	CD34/CD54	99.5
sAML8	M5A	Normal	45	Diagnosis	0	BM	87	CD11c/CD33	99.5
sAML9	M4	Inv(16), del(7)	49	Diagnosis	0	BM	90	CD13/HLA-DR	99
sAML10	M2	t(8;21), −Y, +8	53	Diagnosis	0	BM	79	CD13/HLA-DR	97

Patient	FAB	Karyotype	Age	Disease state of blasts obtained^*	Chemotherapy, including AraC	Material	Blasts before FACS, %	Leukemic-specific markers used for FACS	Blasts after FACS, %
rAML1	M0	t(3;6), del(11), del(12)	38	Relapse	3	BM	95	CD33/34	>95
rAML2	M0	Normal	60	Relapse	2	BM	90	CD13/34	>99.5
rAML3	M2	t(8;21), t(1;10)(minor)	42	Relapse	3	BM	75	CD33/34	99
rAML4	M5A	t(9;11)	22	Relapse	2	BM	80	CD33/HLA-DR	98
rAML5	M2	t(1;9), del(6)	21	Relapse	3	PB	35	CD13/14/33/45	>95
rAML6	M6	Unknown	34	Refractory	2	BM	35	CD15/33	95
rAML7	M1	t(9;22), inv(3), −7	41	Refractory	2	PB	>90	CD34/54	>99.9
rAML8	M5	Unknown	50	Refractory	3	BM	80	CD33/HLA-DR	>95
rAML9	M3	+(13)	56	Refractory	3	BM	97	No sort	97
rAML10	M2	Unknown	53	Refractory	3	BM	94	CD33/34	>95
rAML11	M2	Normal	68	Diagnosis	0	BM	50	CD13/14/33	>95
rAML12	M1	Del(7)	57	Diagnosis	0	BM	95	No sort	95
sAML1	M1	Normal	44	Diagnosis	0	BM	95	No sort	95
sAML2	M5A	Normal	48	Diagnosis	0	BM	95	No sort	95
sAML3	M5A	t(9;11), +8	55	Diagnosis	0	BM	93	CD33/HLA-DR	98.5
sAML4	M4	Unknown	46	Diagnosis	0	BM	60	CD33/HLA-DR	>95
sAML5	M5	t(8;21)	55	Diagnosis	0	BM	96	No sort	96
sAML6	M4	Inv(16), +8, +14, +21	48	Diagnosis	0	BM	60	CD13/CD65	>98
sAML7	M2	t(8;21)	17	Diagnosis	0	PB	75	CD34/CD54	99.5
sAML8	M5A	Normal	45	Diagnosis	0	BM	87	CD11c/CD33	99.5
sAML9	M4	Inv(16), del(7)	49	Diagnosis	0	BM	90	CD13/HLA-DR	99
sAML10	M2	t(8;21), −Y, +8	53	Diagnosis	0	BM	79	CD13/HLA-DR	97

FAB, French-American-British AML subclassification.

Indicates the moments of sampling of the leukemic blasts.